The Instrument of Separation
In the spring of 2023, Agilent Technologies reported something that would have been unremarkable for most companies but was, for Agilent, a kind of seismic event: revenue declined. After three consecutive years of double-digit growth — a run that had taken the company from $5.3 billion to $6.8 billion in annual sales and vaulted its market capitalization past $50 billion — the instruments stopped shipping at quite the same velocity. Pharmaceutical companies, which had gorged on COVID-era diagnostics spending, began digesting their capital budgets. China, which had accounted for roughly a fifth of Agilent's revenue and an outsized share of its growth, turned abruptly hostile to procurement from American life-sciences suppliers. The stock, which had quintupled from its 2015 levels, gave back nearly 30% in a matter of months. Wall Street, with its usual subtlety, began asking whether the Agilent story was "over."
It was not over. It was, in fact, a useful moment to understand what the Agilent story actually is — because the company's durability has never been a function of any single end-market cycle. Agilent makes the machines that separate, identify, and quantify the molecular composition of virtually everything: the purity of a drug compound, the pesticide residue on strawberries, the chemical fingerprint of a lithium-ion battery cathode, the contaminants in a municipal water supply. Its instruments — liquid chromatographs, mass spectrometers, gas chromatographs, spectrophotometers — are the sensory organs of the global quality-assurance infrastructure. They sit in laboratories at Pfizer and Novartis, at the FDA and the EPA, at Samsung SDI and CATL, at every major university chemistry department, at crime labs and food-safety authorities and environmental-testing firms in 110 countries. The installed base numbers in the hundreds of thousands. And every one of those instruments consumes a recurring stream of columns, reagents, sample-preparation kits, and software subscriptions that Agilent sells at gross margins north of 60%.
This is the quiet empire that Ned Barnholt, Bill Sullivan, and Mike McMullen constructed from the wreckage of Hewlett-Packard's instrument division — a business that HP's leadership, in the late 1990s, considered a distraction from the real action in PCs, printers, and enterprise servers. What HP discarded became, over two decades, one of the most consistently profitable analytical-instrument companies on Earth, a textbook study in the compounding power of installed-base economics, and a surprisingly instructive case for any operator who has inherited a legacy business and wondered whether it could become something more.
By the Numbers
Agilent Technologies at a Glance
$6.51BFY2024 revenue
~$42BMarket capitalization (mid-2025)
~27%Operating margin (non-GAAP, FY2024)
~18,000Employees worldwide
$1.4B+Annual free cash flow (FY2024)
110+Countries with Agilent customers
~35%Revenue from recurring consumables & services
3Business segments
What Hewlett-Packard Threw Away
The origin story requires a brief detour through Palo Alto in the 1930s, which is to say through the garage where
Bill Hewlett and Dave Packard built their first audio oscillator in 1939. The founding mythology of Silicon Valley begins with two Stanford electrical engineers and an order from
Walt Disney — eight oscillators for the sound system of
Fantasia — but what gets lost in the retelling is that HP's instrument business was not a precursor to the computing revolution; it
was the company, for decades. Hewlett-Packard made oscilloscopes, signal generators, frequency counters, and, eventually, gas chromatographs and mass spectrometers. The Test &
Measurement division and the Chemical Analysis Group were the original HP — the business that funded everything else.
By the mid-1990s, HP had become a sprawling $40 billion conglomerate, and the instrument divisions, though profitable, were growing in the low single digits while the computing businesses were doubling. Carly Fiorina, who became CEO in 1999, saw the instruments as ballast. The board agreed. On November 1, 1999, Hewlett-Packard spun off its test-and-measurement and chemical-analysis businesses into a new public company. They called it Agilent Technologies — a name conjured by a branding consultancy that was meant to evoke agility and intelligence and instead evoked nothing at all, which may have been the point. The new entity debuted with $8 billion in revenue, 43,000 employees, and the awkward energy of a middle-aged professional who has just been told their services are no longer required.
Edward "Ned" Barnholt, who had spent 30 years at HP and led the Test & Measurement organization, became Agilent's first CEO. He was a measured, operational leader — not a visionary, not a dealmaker, but a man who understood instrument businesses at the circuit-board level. His immediate problem was that Agilent was too many things: semiconductor test equipment, fiber-optic components for telecom networks, electronic test instruments, and life-sciences analytical instruments, all bundled together under a corporate umbrella that lacked strategic coherence. The telecom bubble was about to burst. Semiconductor test was violently cyclical. And the analytical-instruments business — the gas chromatographs, the HPLCs, the mass specs — was the quiet, boring, recurring-revenue gem buried inside a portfolio of volatile hardware businesses.
Barnholt began the triage. When the dot-com crash obliterated demand for telecom components, Agilent's revenue cratered from $8.3 billion in FY2001 to $6 billion in FY2002. The company lost money. Barnholt cut 8,000 jobs. He sold the semiconductor-test business. He divested the healthcare-solutions group. Piece by piece, the conglomerate was being carved down to its core, though it would take another CEO and another decade to finish the job.
1939Bill Hewlett and Dave Packard build their first instrument in a Palo Alto garage.
1966HP enters the analytical-instruments market with gas chromatography products.
1999HP spins off Agilent Technologies; IPO at $30/share raises $2.1 billion — the largest tech IPO in Silicon Valley history at the time.
2001Dot-com crash; Agilent revenue falls from $8.3B to $6B in one year.
2005Bill Sullivan succeeds Ned Barnholt as CEO.
2006Agilent sells its semiconductor-test business to Verigy for $895 million.
2014Agilent spins off Keysight Technologies (electronic test & measurement), completing the focus on life sciences and diagnostics.
2015Mike McMullen becomes CEO and launches the "Build and Buy" strategy.
The Sullivan Pivot
Bill Sullivan, who succeeded Barnholt in 2005, was the architect of the strategic clarity that would define Agilent's next two decades. A PhD chemist who had joined HP in 1977 and risen through the chemical-analysis business, Sullivan understood something that Wall Street kept missing: the life-sciences and chemical-analysis instruments business was fundamentally different from the electronic-test business, not in the physics of measurement but in the economics of the customer relationship.
An oscilloscope buyer purchases a box. A chromatography buyer purchases a system — the instrument, the column, the detector, the software, the method, the validation, the service contract, and a decades-long relationship with the vendor's application scientists who help develop and troubleshoot analytical methods. The instrument is the razor. The columns and reagents are the blades. And the methods — the specific protocols validated by regulators for testing drug purity or food safety or environmental compliance — create switching costs that make the customer relationship almost geological in its permanence. A pharmaceutical company that has validated an analytical method on an Agilent HPLC with an Agilent column and Agilent software, and has submitted that method to the FDA as part of a drug application, does not casually switch to a Waters instrument. The cost of revalidation alone can run into the hundreds of thousands of dollars. The regulatory risk of changing an approved method is existential.
Sullivan saw this. He saw that Agilent was carrying two fundamentally different business models under one corporate roof — a cyclical electronic-test business and a recurring-revenue life-sciences business — and that the market was giving Agilent the multiple of the worse business. In 2014, he executed the move that would define Agilent's modern identity: spinning off the electronic test-and-measurement division as Keysight Technologies, an independent public company.
The Keysight spin was clean and decisive. On November 1, 2014 — exactly 15 years after HP had spun off Agilent — Agilent spun off Keysight, completing a two-generation arc of corporate mitosis. What remained was a pure-play analytical-instruments and life-sciences company with approximately $4 billion in revenue, gross margins above 50%, and a clear strategic identity for the first time in its existence.
We are creating two highly focused companies, each with the ability to allocate capital, develop products, and pursue strategies specifically tailored to their respective markets.
McMullen's Machine
Mike McMullen took over as CEO in March 2015, and the contrast with his predecessors is instructive. Barnholt was an operator who managed a crisis. Sullivan was a strategist who clarified an identity. McMullen was a builder — a chemical engineer by training, a former president of Agilent's Chemical Analysis Group, a man who thought in terms of installed-base penetration, aftermarket attach rates, and the lifetime value of a laboratory customer. Where Sullivan had defined what Agilent would be, McMullen set out to define how it would compound.
His framework was disarmingly simple: "Build and Buy." Build the organic product pipeline — invest in next-generation instruments, expand the consumables portfolio, develop the software platforms that would tie instruments to data to workflows. And buy the businesses that would fill gaps in the portfolio, extend Agilent into adjacent workflows, and — crucially — increase the proportion of revenue that was recurring.
The M&A program that followed was disciplined, mid-market, and relentlessly focused on the aftermarket. McMullen did not chase transformative mega-mergers. He acquired businesses that deepened Agilent's presence inside the laboratory: Dako (clinical diagnostics, pathology), Cobalt Light Systems (Raman spectroscopy), Lasergen (sequencing-by-synthesis chemistry), ProZyme (glycan analysis), Resolution Bioscience (liquid biopsy), and BioTek (microplate readers and imaging) — among others. The deals ranged from tens of millions to roughly $1.1 billion, and they shared a common logic: each one either expanded Agilent's consumables revenue, added a software or services layer, or moved the company deeper into a regulated workflow where switching costs were structurally high.
The BioTek acquisition in 2023, which brought microplate readers into Agilent's cell-analysis portfolio (alongside ACEA Biosciences, acquired in 2018), illustrates the pattern perfectly. Microplate readers are not glamorous instruments. They are the workhorses of drug-discovery laboratories — measuring absorbance, fluorescence, and luminescence in 96-well and 384-well plates, tens of thousands of times a day. The instruments are relatively inexpensive. But the reagent consumption per plate, multiplied across thousands of plates per year, multiplied across thousands of laboratories, creates an annuity stream that compounds quietly in the background while analysts obsess over instrument shipment timing.
McMullen's most consequential strategic bet, though, may be the one that is hardest to see from the outside: the investment in Agilent CrossLab, the company's services and consumables business. CrossLab is not a product line; it is a business model — a platform that bundles instrument maintenance, compliance services, asset management, consumable columns and reagents, and workflow-optimization consulting into multi-year enterprise agreements. It is, in essence, Agilent's attempt to transform itself from a capital-equipment vendor into a laboratory-infrastructure-as-a-service provider. CrossLab grew to roughly $1.6 billion in revenue by FY2024, with margins that exceed the corporate average and retention rates that approach 95%.
The beauty of CrossLab is that it grows when our customers' labs grow, and it doesn't decline when their capital budgets tighten. It's the most resilient part of our business.
The Three Kingdoms
Modern Agilent is organized into three reporting segments, and the architecture reveals the strategic logic more clearly than any mission statement.
Life Sciences and Applied Markets Group (LSAG) is the flagship — the instruments business. Gas chromatographs, liquid chromatographs, mass spectrometers, spectroscopy systems, cell-analysis instruments, and the software that runs them. LSAG accounted for roughly $3.1 billion of FY2024 revenue, or about 48% of the total. These are the machines that sit on laboratory benches around the world, and their placement drives the entire downstream economics of the company. LSAG's gross margins are in the mid-50s, pressured by the capital-equipment nature of the business and the R&D intensity required to maintain technology leadership.
Agilent CrossLab Group (ACG) is the aftermarket engine. Consumables (columns, sample-preparation products, reagents), services (instrument maintenance, compliance, enterprise asset management), and the software platform that ties laboratory workflows together. ACG generated approximately $1.6 billion in FY2024 — about 24% of total revenue — with gross margins well above 60%. This is the segment that gives Agilent its durability. When pharmaceutical companies freeze capital budgets, they do not stop buying columns. When a government regulator mandates a new pesticide-screening method, the testing laboratories need new consumables, not necessarily new instruments.
Diagnostics and Genomics Group (DGG) is the youngest and most volatile segment, built largely through acquisition — Dako's pathology business, the nucleic-acid solutions business, and the genomics portfolio. DGG generated roughly $1.8 billion in FY2024, or about 28% of total revenue, with margins that have been compressed by the normalization of COVID-related demand (Agilent's nucleic-acid products were used in PCR-test manufacturing) and the structural challenges of the clinical-diagnostics market. DGG is the segment where Agilent's strategic ambitions are most exposed — it is a bet that the same installed-base economics that work in analytical chemistry can be extended into clinical pathology and genomics. The jury remains out.
🔬
Agilent's Three Segments
FY2024 revenue and operating profile
| Segment | FY2024 Revenue (est.) | % of Total | Key Products | Margin Profile |
|---|
| Life Sciences & Applied Markets (LSAG) | ~$3.1B | ~48% | LC, GC, MS, spectroscopy, cell analysis | Mid-50s gross |
| Agilent CrossLab (ACG) | ~$1.6B | ~24% | Columns, reagents, services, software | 60%+ gross |
| Diagnostics & Genomics (DGG) |
The Column Is the Strategy
To understand Agilent's competitive position, you have to understand what a chromatography column actually does and why its economics are so extraordinary.
A chromatographic column is a tube — typically stainless steel or fused silica, ranging from a few centimeters to several meters in length — packed with stationary-phase material (silica particles, polymer beads, or carbon) whose surface chemistry has been precisely engineered to interact differently with different molecules. You inject a mixture into one end. A mobile phase — a solvent or gas — pushes the mixture through the column. Different molecules interact differently with the stationary phase, so they emerge from the other end at different times. This is separation. The detector at the far end identifies and quantifies what comes out.
The column is a consumable. It degrades with use. Depending on the application, a column might last for hundreds of injections or thousands, but eventually the stationary-phase chemistry breaks down, peak shapes broaden, resolution degrades, and the analyst replaces it. A single HPLC column costs anywhere from $200 to $2,000. A high-throughput pharmaceutical QC laboratory might consume dozens per month. Multiplied across Agilent's installed base — hundreds of thousands of LC and GC instruments worldwide — the column business alone generates hundreds of millions of dollars in annual revenue at gross margins that likely exceed 70%.
But the economics go deeper than simple razor-and-blade arithmetic. Columns are method-specific. When a pharmaceutical company develops an analytical method for testing drug purity — say, an HPLC method for assaying the active ingredient in a tablet — that method specifies the exact column (brand, dimensions, particle size, stationary-phase chemistry), the exact mobile-phase composition, the exact flow rate, the exact temperature, and the exact detector settings. This method is then validated according to ICH guidelines, submitted to the FDA as part of the drug application, and locked in place for the commercial life of the drug. The column specified in the method becomes, in effect, a regulatory mandate. Switching to a competitor's column would require method revalidation — a process that can take months and cost six figures. For a blockbuster drug, the risk of a failed revalidation, and the potential delay to commercial supply, makes the switching cost functionally infinite.
This is why Agilent's CrossLab business is so resilient, and why the company's competitive moat is deeper than a simple market-share analysis would suggest. The moat is not in the instruments per se — Waters, Shimadzu, Thermo Fisher, and Bruker all make excellent chromatographs and mass spectrometers. The moat is in the method — the validated, regulated, locked-in combination of instrument, column, software, and protocol that the customer cannot easily change. Agilent's strategy, under McMullen, has been to maximize the number of methods validated on Agilent systems and to expand the aftermarket revenue that flows from each validated method.
The China Variable
Every analytical-instruments company has a China story, and Agilent's is both more instructive and more uncomfortable than most.
China represented approximately 20% of Agilent's revenue through the early 2020s — a proportion that had grown steadily as Chinese pharmaceutical companies expanded, as environmental-monitoring mandates proliferated under Xi Jinping's early environmental reforms, and as Chinese universities built world-class analytical-chemistry departments. Agilent was the dominant Western brand in Chinese laboratories. Its local sales force was large, well-trained, and deeply embedded in the academic and pharmaceutical customer base.
Then the ground shifted. Beginning in 2023, the Chinese government — motivated by a combination of economic nationalism, geopolitical tension with the United States, and a desire to build domestic alternatives to Western scientific infrastructure — began steering procurement decisions toward domestic instrument manufacturers. Shimadzu, with its manufacturing footprint in Japan and closer cultural ties, was less affected. But American brands, Agilent included, faced a systematic chill: purchase orders delayed, tenders restructured to favor local suppliers, and a growing ecosystem of Chinese instrument companies — Shimadzu's local competitors, essentially — that were improving rapidly and competing on price.
Agilent's China revenue declined meaningfully in FY2023 and FY2024. Management has been measured in its public commentary, acknowledging "softness" and "extended deal cycles" without naming the geopolitical dynamics explicitly. But the implications are structural: the assumption that China would be a high-single-digit growth engine for Agilent for the foreseeable future — an assumption baked into many analysts' long-term models — now carries a significant asterisk.
The China question is not whether Agilent will lose all its Chinese business. It won't. The installed base is too large, the methods too deeply validated, the applications too technically demanding for domestic competitors to displace overnight. The question is whether China reverts to a growth contributor or becomes a slowly eroding legacy market — and whether the rest of Agilent's geographic portfolio (the Americas, Europe, non-China Asia-Pacific) can compensate for the lost growth.
We continue to see a more cautious spending environment in China, particularly in the pharma and academic segments. We're adjusting our expectations accordingly while maintaining our investment in the region.
Pharma's Pendulum
Pharmaceutical and biotechnology companies account for roughly one-third of Agilent's revenue — the single largest end-market — and the relationship between Agilent's growth rate and pharma's capital-expenditure cycle is the most important variable in the company's near-term financial model.
The COVID era was extraordinarily good to Agilent's pharma business. Vaccine development, mRNA manufacturing, therapeutic-antibody production, and the vast expansion of QC testing capacity for COVID-related therapies drove an unprecedented investment cycle in analytical instrumentation. Pharma companies were not only buying instruments; they were accelerating laboratory buildouts, doubling QC capacity, and stockpiling consumables. Agilent's revenue growth hit 18% in FY2022. The CrossLab and consumables businesses were running at full capacity.
What followed was the hangover. By mid-2023, pharma capital budgets began normalizing. The large biopharma companies — Pfizer, Roche, Novartis, AstraZeneca — had overbuilt capacity during COVID and were now rationalizing. Biotech funding contracted as interest rates rose, squeezing the smaller companies that had been enthusiastic instrument buyers. Agilent's pharma-related revenue declined in the mid-single digits in FY2023 and continued to face headwinds into FY2024.
The structural case for pharma instrumentation demand remains intact — the drug-development pipeline is enormous, regulatory requirements for analytical testing are increasing, not decreasing, and the shift toward biologics and cell-and-gene therapies requires more sophisticated analytical workflows, not fewer. But the cyclical overlay is real. Pharma is Agilent's most important customer, and pharma's capital-spending cycles are long, lumpy, and driven by forces (patent cliffs, clinical-trial outcomes, FDA policy, biotech funding markets) that Agilent cannot control.
The strategic response has been to tilt the revenue mix toward consumables and services — the components of the pharma relationship that are less cyclical than instrument sales. If Agilent can grow CrossLab's share of pharma revenue from roughly 35% to 40% or higher, the company's overall revenue volatility declines meaningfully. This is the single most important operational priority McMullen has articulated, and it explains the M&A focus on consumables and software businesses.
The Software Layer
The least visible but potentially most consequential investment Agilent has made in the McMullen era is in software — specifically, in laboratory-informatics platforms that manage data, workflows, and compliance across the analytical laboratory.
Agilent's OpenLab platform is the company's attempt to build a software layer that spans the entire laboratory workflow: instrument control, data acquisition, data analysis, reporting, and integration with laboratory information management systems (LIMS). OpenLab competes with Thermo Fisher's Chromeleon, Waters' Empower, and a constellation of smaller LIMS vendors, and the competitive dynamics are intense. But the strategic logic is clear: if Agilent can become the operating system of the analytical laboratory — the software layer that ties instruments, data, and workflows together — the switching costs compound exponentially.
A laboratory running OpenLab across 50 instruments has made a systems-level commitment that is orders of magnitude harder to reverse than a single-instrument purchase decision. The data is in Agilent's format. The methods are validated in Agilent's software. The compliance records — audit trails, electronic signatures, 21 CFR Part 11 compliance — are all embedded in Agilent's platform. Ripping out OpenLab and replacing it with a competitor's software is a multi-year project with profound regulatory risk.
Agilent has also invested in cloud-based laboratory services — remote diagnostics, predictive maintenance, instrument-utilization analytics — that layer on top of the installed base and create new recurring-revenue streams. These are early-stage businesses, but they represent the logical extension of the installed-base strategy: once you own the instrument and the consumable and the software, you can begin selling insight.
The risk, as with all enterprise-software ambitions from hardware companies, is execution. Agilent is an instrument company. Software is a different discipline — different talent, different development cycles, different customer-success models. The history of industrial companies that have tried to "become software companies" is littered with expensive failures. McMullen has been careful to frame the software strategy as complementary to, not a replacement for, the core instruments business. Whether that discipline holds as the temptation to "platform-ize" grows remains to be seen.
The Oligopoly of Measurement
The global analytical-instruments market is one of the most concentrated oligopolies in industrial technology, and the barriers to entry are formidable — not because the physics is impossibly difficult (many university labs have built one-off mass spectrometers) but because the qualification and validation infrastructure that surrounds the instruments is effectively insurmountable for new entrants.
Four companies dominate: Agilent, Thermo Fisher Scientific, Waters Corporation, and Danaher (through its Sciex and Beckman Coulter businesses). Shimadzu and Bruker are significant players in specific segments. Together, these six companies control the vast majority of the global chromatography, mass spectrometry, and spectroscopy markets.
The oligopoly is sustained by several reinforcing dynamics. First, the regulatory qualification process: a laboratory that has qualified an Agilent instrument for GMP use has invested months and significant capital in the installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) protocols. Second, the method-validation lock-in described above. Third, the application-science expertise: Agilent employs hundreds of PhD-level application scientists who develop and publish analytical methods, work directly with customers on method development, and train laboratory personnel. This scientific field force is a competitive weapon that new entrants cannot replicate without decades of investment.
Fourth — and this is underappreciated — the service and support infrastructure. Analytical instruments are not consumer electronics. A mass spectrometer that goes down in a pharmaceutical QC lab can halt production of a drug. Response time matters. Agilent maintains a global service network with same-day or next-day response capabilities in most major markets, backed by a parts-and-consumables logistics chain that is itself a competitive moat.
The oligopoly is not static, however. Thermo Fisher, through its acquisitions of Life Technologies, Phenom-World, and PPD, has become an analytically diversified colossus with $44 billion in revenue — seven times Agilent's scale. Waters, under new CEO Udit Batra, has been aggressively investing in next-generation LC platforms and software. Danaher, the master of the operating-system playbook, continues to execute its Danaher Business System across its analytical portfolio. And the Chinese domestic competitors — Shimadzu Instruments (Suzhou), Fuli Instruments, Techcomp — are improving faster than the Western incumbents would like to admit.
In this industry, you don't just sell a product. You sell a validated workflow. And workflows, once established, are extraordinarily difficult to displace.
The Succession Question
In September 2024, Agilent announced that Padraig McDonnell would succeed Mike McMullen as CEO, effective March 2025. McDonnell, who had served as president of Agilent's largest segment (LSAG) and, before that, as the company's chief commercial officer, was an internal promotion — a signal of strategic continuity.
McMullen's tenure had been remarkable by any operational measure. From FY2015 to FY2024, he had grown Agilent's revenue from approximately $4.0 billion to $6.5 billion, expanded operating margins by roughly 500 basis points, executed more than a dozen acquisitions, and compounded the stock at approximately 20% annually. He had transformed a post-spinoff instrument company into a recurring-revenue-weighted laboratory-solutions provider. The "Build and Buy" framework had worked.
McDonnell inherits a company in a different position than the one McMullen inherited. The easy growth — the post-Keysight-spinoff multiple expansion, the COVID-era demand surge, the China boom — has been harvested. What remains is the harder, more operationally demanding work of compounding a $6.5 billion business at mid-to-high single-digit growth rates while maintaining margins and deploying capital efficiently. The new CEO's stated priorities — accelerating the shift to recurring revenue, deepening the software and digital platforms, expanding in biopharma and diagnostics — are extensions of McMullen's strategy, not departures from it.
The question is whether Agilent's organizational culture, which was built for the McMullen era's acquisition-driven growth, can adapt to a period that may require more organic innovation and fewer transformative deals. McMullen was a dealmaker and an integrator. McDonnell, by reputation, is more of a commercial operator — a closer of enterprise agreements, a builder of sales-force discipline. Different era, different tool.
The PFAS Tailwind and Other Secular Currents
Beneath the cyclical noise of pharma budgets and China procurement, several structural trends are quietly compounding demand for Agilent's instruments and consumables.
PFAS — per- and polyfluoroalkyl substances, the "forever chemicals" that have contaminated drinking water, agricultural soil, and human blood across the developed world — may be the most consequential regulatory tailwind Agilent has encountered since the Clean Air Act created the environmental-testing industry in the 1970s. The EPA's 2024 decision to set enforceable limits on six PFAS compounds in drinking water, at concentrations as low as 4 parts per trillion, requires analytical capabilities that only a handful of instruments can deliver: triple-quadrupole LC-MS/MS systems with the sensitivity to detect molecules at the parts-per-trillion level.
Agilent's 6470 and 6495 triple-quadrupole mass spectrometers are among the instruments qualified for EPA Method 533 and Method 537.1, the standard methods for PFAS analysis. Every municipal water utility in the United States — there are roughly 50,000 of them — will need access to PFAS testing capability, either through internal laboratories or commercial testing services. The commercial environmental-testing laboratories (Eurofins, SGS, Bureau Veritas) are already expanding their PFAS-testing capacity and purchasing instruments aggressively.
Beyond PFAS, the shift toward biologics and cell-and-gene therapies in pharmaceutical development is creating demand for new analytical workflows that did not exist a decade ago. Characterizing a monoclonal antibody requires a different analytical toolkit than characterizing a small-molecule drug — multi-attribute methods (MAMs), intact-mass analysis, glycan profiling, charge-variant analysis — and Agilent has invested heavily in building the instruments, columns, and software for these workflows.
The energy transition is another, less obvious driver. Battery manufacturers need to characterize cathode and anode materials for impurities at the parts-per-billion level. Hydrogen-fuel-cell developers need to analyze gas purity. Semiconductor manufacturers, racing to build domestic fabrication capacity, need ultra-trace-level contamination analysis. All of these applications run on chromatography and mass spectrometry. All of them need columns and reagents.
A Machine for Compounding
The simplest way to understand Agilent is as a compounding machine with three gears.
The first gear is instrument placement — putting a new chromatograph or mass spectrometer on a laboratory bench. This is the most cyclical part of the business, the most capital-intensive, and the lowest-margin. But each instrument placed creates a multi-decade revenue stream.
The second gear is the aftermarket — the columns, reagents, service contracts, and software subscriptions that flow from the installed base. This is higher-margin, more recurring, and less cyclical. It is the engine that converts volatile instrument sales into durable cash flow.
The third gear is the method and workflow lock-in — the regulatory and procedural infrastructure that anchors the customer to Agilent's ecosystem for years or decades. This is not a revenue line; it is a structural condition that protects the first two gears from competitive displacement.
McMullen's genius was recognizing that the second and third gears were underinvested and that the company's strategic priority should be maximizing the lifetime value of each installed instrument — not just through consumables and service, but through software, digital services, and enterprise-level relationships that transform transactional customers into annuity streams.
The result is a business that generates roughly $1.4 billion in annual free cash flow — a 22% free-cash-flow yield on revenue — and returns most of it to shareholders through buybacks and a growing dividend. The balance sheet carries modest leverage. The capital requirements are low relative to revenue. And the installed base, numbering in the hundreds of thousands of instruments, continues to consume columns and reagents regardless of whether a single new instrument ships this quarter.
In the spring of 2023, when Agilent's stock was falling and analysts were fretting about the pharma cycle and China, the CrossLab business grew. The columns kept shipping. The service contracts renewed. The methods stayed validated. The machine kept compounding.
In the basement of a pharmaceutical QC laboratory in Basel, or a food-safety testing facility in Shenzhen, or an environmental lab in New Jersey, an Agilent HPLC hums through its thousandth injection of the day, pushing solvent through a $400 column packed with 1.8-micron silica particles, separating molecules that no human eye will ever see, generating data that will be reviewed, approved, and archived according to methods that were validated years ago and will not change for years to come. The column will be replaced next week. Agilent will ship another one.
Agilent's trajectory — from HP castoff to one of the most consistently profitable analytical-instrument companies on Earth — encodes a set of operating principles that apply far beyond the laboratory. These are not abstract management maxims. They are strategic choices, repeatedly validated by financial performance, that operators in any installed-base or recurring-revenue business can study and adapt.
Table of Contents
- 1.Spin until you're pure.
- 2.Sell the razor at a profit, then own the blade.
- 3.Make the method, not the instrument, the moat.
- 4.Acquire the aftermarket, not the headline.
- 5.Build the software layer before someone else does.
- 6.Price for the lifetime, not the transaction.
- 7.Staff the field with scientists, not salespeople.
- 8.Let regulation be your distribution.
- 9.Compound the base, don't chase the cycle.
- 10.Promote operators, not visionaries.
Principle 1
Spin until you're pure.
Agilent's defining strategic act was not an acquisition or a product launch — it was a subtraction. The 2014 Keysight spin-off completed a 15-year process of corporate simplification that began with HP's decision to spin off Agilent itself. Each spin removed a business whose cyclicality, capital requirements, or customer dynamics were diluting the market's understanding of the remaining company. Post-Keysight, Agilent's revenue-per-employee economics, margin structure, and growth profile all improved — not because the business changed, but because the market could finally see it clearly.
The Keysight spin was not a response to activist pressure or a balance-sheet restructuring. It was a proactive recognition that two good businesses can be worth less together than apart when they confuse capital allocation, management attention, and investor expectations. Sullivan saw that Agilent's recurring-revenue life-sciences business was being valued like a cyclical electronic-test business, and the only way to fix the misvaluation was to eliminate the source of confusion.
Benefit: A pure-play identity enables precise capital allocation, attracts the right investors, and allows management to make decisions optimized for one business model rather than compromising across two.
Tradeoff: Spin-offs sacrifice diversification. Post-Keysight, Agilent became more exposed to pharma capital cycles and China risk than the combined entity would have been. Purity concentrates risk.
Tactic for operators: If your company operates two business models with fundamentally different revenue profiles (e.g., one recurring, one project-based), the market is almost certainly misvaluing the better business. Model the sum-of-the-parts value. If the gap is significant, separation — spin, carve-out, or sale — may create more value than any product launch.
Principle 2
Sell the razor at a profit, then own the blade.
The razor-and-blade model is well understood. Agilent's refinement is that the "razor" — the instrument — is itself sold at healthy margins (gross margins in the mid-50s for LSAG), creating a business where the initial sale is profitable and the aftermarket is highly profitable. This is not the Gillette or Keurig model of subsidizing the hardware to capture the consumable; it is a model where every component of the customer relationship generates positive economics.
The structural reason Agilent can price instruments profitably rather than subsidizing them is the oligopolistic market structure and the regulatory qualification costs described in Part I. When a pharmaceutical company is choosing between an Agilent HPLC and a Waters HPLC for a GMP application, the decision is not primarily driven by instrument price — it is driven by the total cost of ownership (including validation, training, service, and consumables), the application-science support, and the service infrastructure. Price competition exists at the margin, but it is not the primary competitive dimension.
Benefit: Profitable initial sales generate cash flow that can be reinvested in R&D and service infrastructure, creating a virtuous cycle. The company is never hostage to the aftermarket to reach profitability.
Tradeoff: Profitable instrument pricing leaves room for lower-cost competitors — particularly Chinese domestic manufacturers — to undercut on price in less regulated applications.
Tactic for operators: If you're designing a razor-and-blade business, resist the temptation to subsidize the initial sale unless you can guarantee aftermarket capture through genuine lock-in (not just habit). A profitable initial transaction preserves strategic flexibility.
Principle 3
Make the method, not the instrument, the moat.
Agilent's deepest competitive advantage is not the chromatograph or the mass spectrometer — it is the validated analytical method that specifies the Agilent instrument, the Agilent column, and the Agilent software. The method is the customer's intellectual property, validated through months of laboratory work, submitted to regulators, and locked into manufacturing processes for years or decades.
This insight — that the moat lives in the workflow, not the product — drives Agilent's investment in application-science support, method-development collaborations, and the publication of application notes that serve as de facto standard methods. Agilent publishes hundreds of application notes per year, many co-authored with customers or regulatory laboratories, each one demonstrating that a specific analytical problem can be solved using a specific combination of Agilent instrument, column, and software. These publications function as soft standards: when a new analyst needs to develop a PFAS method, they Google "PFAS analysis HPLC method" and find an Agilent application note.
📋
The Method Lock-In Cycle
How validated methods create structural switching costs
Step 1Customer selects Agilent instrument, column, and software for method development.
Step 2Application scientists collaborate on method optimization over weeks or months.
Step 3Method is validated per ICH/FDA guidelines; validation documentation locked.
Step 4Method submitted to regulators as part of drug application or compliance filing.
Step 5For the commercial life of the product (often 10–20 years), the customer must use the specified Agilent consumables.
Benefit: Method lock-in creates switching costs that are regulatory, not merely contractual. Competitors cannot displace Agilent by offering a better product; they can only win new methods on new instruments.
Tradeoff: The moat is strongest in regulated markets (pharma, food safety, environmental). In academic and research settings, where methods are not formally validated, the switching costs are much lower.
Tactic for operators: Identify the customer workflow — not just the product use case — and invest in becoming inseparable from the validated process. The deepest moats are built not by making the best product but by becoming embedded in the customer's compliance infrastructure.
Principle 4
Acquire the aftermarket, not the headline.
McMullen's M&A strategy was notably unsexy. No transformative mega-mergers. No "strategic pivots" into adjacent industries. The acquisitions — BioTek, Cobalt Light Systems, ProZyme, Resolution Bioscience, ACEA Biosciences — were mid-market deals, typically under $500 million, that shared a common characteristic: they expanded Agilent's consumables, reagents, or software revenue within the existing customer base.
The BioTek acquisition is the cleanest illustration. BioTek makes microplate readers — instruments that cost $20,000 to $100,000 each and sit in drug-discovery laboratories. The instruments are relatively simple. But each microplate reader consumes reagent kits, microplates, and software licenses, and the drug-discovery laboratory that has standardized on BioTek readers typically runs thousands of plates per week. The aftermarket revenue per installed instrument is a multiple of the instrument's purchase price over its lifetime.
🛒
McMullen-Era Acquisitions
Selected deals illustrating the aftermarket-first strategy
| Acquisition | Year | Strategic Logic | Revenue Type |
|---|
| Dako (pathology) | Pre-McMullen (2012) | Consumables-heavy diagnostic workflows | Recurring |
| ACEA Biosciences | 2018 | Cell-analysis reagents and instruments | Recurring |
| BioTek Instruments | 2023 | Microplate readers; high consumable consumption | |
Benefit: Acquiring aftermarket revenue is accretive to margins, reduces cyclicality, and deepens customer relationships without the integration risk of platform acquisitions.
Tradeoff: This approach caps the upside. Mid-market consumables acquisitions don't transform the company's growth rate or create new markets. They compound existing advantages — powerful but unspectacular.
Tactic for operators: When evaluating acquisitions, rank targets by their aftermarket revenue ratio (recurring revenue / total revenue). A $200M-revenue consumables business with 70% gross margins and 95% retention is almost always a better acquisition than a $500M-revenue hardware business with 40% margins and cyclical demand.
Principle 5
Build the software layer before someone else does.
Agilent's investment in OpenLab and laboratory-informatics software reflects a strategic recognition that the most defensible position in any technology ecosystem is the data layer. The company that controls how laboratory data is acquired, stored, analyzed, and reported controls the customer relationship at a level that transcends any individual instrument purchase.
The challenge is execution. Instrument companies think in hardware cycles — multi-year development timelines, physical product launches, field-service deployments. Software companies think in sprints, continuous deployment, and user experience. Agilent has invested in hiring software talent and building cloud infrastructure, but the cultural gap between an instrument-engineering organization and a software-development organization is real and persistent.
Benefit: A dominant software layer creates compounding switching costs that scale with the number of instruments connected, the volume of data accumulated, and the depth of compliance records stored.
Tradeoff: Software development requires different talent, processes, and management approaches than instrument development. The risk of building mediocre software that satisfies neither the market nor the organization is high.
Tactic for operators: If you sell hardware into a workflow, invest in the software layer now — even before the ROI is obvious. The window to own the data layer closes when a third-party platform (or a competitor) does it first. But staff the effort with genuine software talent, not redeployed hardware engineers.
Principle 6
Price for the lifetime, not the transaction.
Agilent's CrossLab enterprise agreements represent a shift from transactional consumables sales to multi-year contracts that bundle instruments, consumables, service, and software into a single relationship. These agreements typically span three to five years and are priced based on laboratory size, instrument count, and application complexity — not on individual consumable units.
This pricing model serves multiple strategic purposes: it increases customer lifetime value by locking in multi-year commitments; it provides revenue visibility that smooths quarterly volatility; it positions Agilent as a laboratory-infrastructure partner rather than a product vendor; and it creates an information asymmetry — Agilent gains deep insight into the customer's laboratory operations, instrument utilization, and consumables consumption patterns, which enables upselling, capacity planning, and proactive service.
Benefit: Enterprise agreements convert transactional customers into annuity relationships with significantly higher lifetime value and dramatically lower churn.
Tradeoff: Enterprise pricing requires a sophisticated sales force capable of selling outcomes rather than products. It extends sales cycles and requires executive-level customer relationships. Not every customer is ready for or interested in a bundled relationship.
Tactic for operators: Map your customer base by lifetime value. Identify the top 20% of customers who generate 80% of repeat revenue. Design a bundled offering — products, services, data, support — that converts the transactional relationship into a multi-year commitment. Price it at a slight discount to à la carte to incentivize commitment, but ensure the bundle includes services the customer doesn't currently buy.
Principle 7
Staff the field with scientists, not salespeople.
Agilent's field organization includes hundreds of application scientists — PhDs and masters-level chemists who work directly with customers on method development, troubleshooting, and application optimization. These are not sales engineers who happen to have a science background; they are practicing scientists who publish in peer-reviewed journals, present at conferences, and develop the application notes that function as informal standards.
This scientific field force serves as both a competitive weapon and a customer-acquisition channel. When a university professor publishes a paper using an Agilent method developed in collaboration with an Agilent application scientist, every subsequent researcher who cites that paper becomes a potential Agilent customer. When a pharmaceutical company needs to develop a new analytical method for a biologics program, the Agilent application scientist who collaborates on the development becomes the reason the method is validated on Agilent equipment.
Benefit: Application scientists create customer relationships built on technical trust, not commercial negotiation. They generate IP (application notes, methods) that functions as marketing collateral and competitive positioning.
Tradeoff: PhD-level scientists are expensive and difficult to manage in a commercial organization. The ROI is long-dated and hard to attribute directly to revenue. Cutting application-science headcount is the fastest way to improve short-term margins and the surest way to erode long-term competitive position.
Tactic for operators: If your product requires customer expertise to deploy, invest in field experts who can build the customer's capability alongside the sale. The expert's output (case studies, methods, publications) becomes a self-reinforcing marketing asset that no amount of advertising can replicate.
Principle 8
Let regulation be your distribution.
Every new environmental regulation, food-safety standard, or pharmaceutical quality requirement creates demand for analytical testing — and therefore for analytical instruments and consumables. The EPA's PFAS drinking-water standards. The EU's updated pesticide maximum residue limits. China's environmental-monitoring mandates. The FDA's increasing requirements for characterization of biologics. Each regulatory action functions as a demand signal that is mandatory, not discretionary.
Agilent has systematically positioned itself at the intersection of regulation and analytical capability by investing in the development of methods that meet specific regulatory requirements. When the EPA publishes a new analytical method for PFAS detection, Agilent's instruments and columns are among those specified in the method. When the European Pharmacopoeia updates a monograph for a specific drug substance, Agilent application scientists ensure that the updated method runs on Agilent equipment.
Benefit: Regulatory-driven demand is non-discretionary and recurring. It is immune to economic cycles, customer budget pressures, and competitive pricing. Once an instrument is specified in a regulatory method, the revenue annuity is measured in decades.
Tradeoff: Regulatory timelines are unpredictable. A regulatory change that was expected in 2024 might not arrive until 2027 — or might never arrive at all. Building product and sales capacity for anticipated regulation that doesn't materialize wastes capital.
Tactic for operators: Monitor the regulatory pipeline in your industry with the same rigor you monitor your product pipeline. For each anticipated regulation, ask: what capability will our customers need to comply, and can we be the standard for that capability? Invest in partnerships with regulatory bodies, standards organizations, and the testing laboratories that will define the standard methods.
Principle 9
Compound the base, don't chase the cycle.
The most important number in Agilent's financial model is not revenue growth or operating margin — it is the installed-base growth rate. Every instrument shipped today generates consumables and service revenue for 10 to 20 years. The compounding effect of steadily growing the installed base, even at modest rates, creates an enormous and growing annuity that is largely invisible in quarterly revenue figures but accounts for the majority of Agilent's long-term value.
McMullen understood this intuitively. His investment priorities — CrossLab, consumables acquisitions, software platforms — were all designed to maximize the revenue per installed instrument. Even during the FY2023–2024 downturn, when instrument shipments declined, CrossLab continued to grow because the installed base was still expanding (albeit more slowly) and the aftermarket attach rate was increasing.
Benefit: Installed-base economics create a self-reinforcing flywheel where the annuity grows even in periods of declining instrument sales. This dramatically reduces the cyclicality of the overall business.
Tradeoff: Installed-base strategies are slow. They do not produce hockey-stick growth curves. They are difficult to explain to growth-oriented investors and require management discipline to maintain during periods when competitors are chasing market share through aggressive instrument pricing.
Tactic for operators: Calculate the lifetime value of each customer acquisition, including all downstream revenue streams. If the aftermarket LTV is a large multiple of the initial transaction value, orient your entire organization — R&D, sales, service, M&A — around maximizing installed-base growth and aftermarket attach rates, even at the expense of near-term revenue growth.
Principle 10
Promote operators, not visionaries.
Agilent's CEO succession from Barnholt to Sullivan to McMullen to McDonnell follows a consistent pattern: each leader came from within the organization, had deep domain expertise in the core business, and was promoted based on operational track record rather than visionary rhetoric. None was a celebrity CEO. None was brought in from outside the industry to "transform" the company. Each was a builder who understood the specific competitive dynamics, customer relationships, and technical requirements of the analytical-instruments business.
This is not coincidence. It reflects a strategic judgment that the analytical-instruments business rewards operational compounding — steady execution, disciplined capital allocation, incremental improvement — more than it rewards visionary disruption. The installed-base economics, the regulatory lock-in, the oligopolistic market structure — these are advantages that compound with patient, expert management and can be destroyed by aggressive pivots.
Benefit: Internal promotion ensures strategic continuity, preserves institutional knowledge, and maintains customer and employee relationships that take years to build.
Tradeoff: Internal succession risks insularity. If the competitive environment shifts dramatically — if, say, a platform technology disrupts the chromatography paradigm entirely — an internally promoted leader may lack the outside perspective to recognize and respond.
Tactic for operators: Build a bench of internal CEO candidates by rotating high-potential leaders through multiple business segments, giving them P&L responsibility early, and evaluating them on operational metrics (customer retention, margin expansion, capital efficiency) rather than visionary qualities. Save the outside hire for genuine existential crises.
Conclusion
The Geometry of Patience
Agilent's playbook is not about speed. It is about geometry — the shape of a business designed so that every instrument sold, every method validated, every column shipped, and every service contract signed adds a compounding layer to a structure that grows more durable with each passing year. The principles are not individually revolutionary. Spin until you're pure. Sell the razor at a profit. Own the method, not just the machine. Acquire the aftermarket. Build the software layer. Price for the lifetime. Staff the field with scientists. Let regulation distribute your product. Compound the base. Promote the operators.
What makes them powerful is their coherence — each principle reinforces the others. Method lock-in makes the aftermarket sticky. Aftermarket stickiness justifies instrument pricing. Instrument pricing funds application-science investment. Application-science investment creates new method lock-in. The result is a flywheel that turns slowly but generates enormous torque.
Operators studying Agilent will find no silver bullets. They will find a machine — methodical, patient, precise — that converts installed-base economics into durable, compounding free cash flow. The lesson is less about analytical instruments than about the discipline of building a business where every transaction is the beginning of a relationship, not the end of a sale.
Part IIIBusiness Breakdown
The Business at a Glance
Vital Signs
Agilent Technologies — FY2024
$6.51BTotal revenue
~27%Non-GAAP operating margin
~$1.4BFree cash flow
~$42BMarket capitalization (mid-2025)
~18,000Employees worldwide
$5.29Non-GAAP EPS (FY2024)
~20%R&D as % of revenue
~95%CrossLab customer retention rate
Agilent Technologies sits in an unusual position among life-sciences and analytical-instruments companies: large enough to operate a global service network and sustain $1.3 billion in annual R&D investment, but small enough — relative to Thermo Fisher's $44 billion or Danaher's $24 billion — that individual product cycles and geographic markets meaningfully move the needle. FY2024 represented a year of stabilization after the sharp corrections in pharma spending and China demand that defined FY2023. Revenue of approximately $6.51 billion was roughly flat year-over-year on an organic basis, with CrossLab and select diagnostics categories providing resilience while LSAG instrument sales remained soft. Non-GAAP operating margins held near 27%, reflecting the company's cost discipline and the favorable mix shift toward higher-margin consumables and services.
The company's capital-light model — analytical instruments do not require heavy manufacturing infrastructure on the scale of semiconductor fabs or pharmaceutical plants — generates free-cash-flow conversion consistently above 100% of net income. This cash flow funds a balanced capital-return program: share repurchases averaging $750 million to $1 billion annually, a dividend that has grown at a double-digit CAGR since its initiation, and a disciplined M&A program that has deployed roughly $5 billion in acquisition capital over the McMullen era.
How Agilent Makes Money
Agilent's revenue derives from three interconnected streams, each with distinct margin profiles, cyclical sensitivities, and growth characteristics.
FY2024 estimated revenue by segment and type
| Revenue Stream | FY2024 Est. | % of Total | Gross Margin | Growth Profile |
|---|
| LSAG — Instruments | ~$3.1B | ~48% | Mid-50s% | Cyclical, mid-single-digit trend |
| ACG — CrossLab (consumables, services, software) | ~$1.6B | ~24% | 60%+ | Resilient, high-single-digit trend |
| DGG — Diagnostics & Genomics |
Instrument sales (LSAG) are the entry point. An Agilent liquid chromatograph system (instrument, detector, autosampler, column compartment) typically sells for $50,000 to $250,000 depending on configuration. Mass spectrometers range from $150,000 to over $1 million for high-end triple-quadrupole and Q-TOF systems. These are capital-equipment purchases that follow laboratory construction cycles, pharma R&D budgets, and regulatory mandates. Instrument revenue is inherently lumpy — a single large pharma account can place or defer a $5 million order based on quarterly budget dynamics.
CrossLab (ACG) is the compounding engine. Chromatography columns ($200–$2,000 each, consumed regularly), sample-preparation products, reagents, and reference standards generate recurring consumables revenue. Multi-year service contracts (preventive maintenance, compliance qualification, emergency repair) provide predictable service revenue. And laboratory-informatics software subscriptions — OpenLab, iLab, and related platforms — add a growing digital-services layer. CrossLab's approximately 95% retention rate and high-single-digit organic growth rate make it the segment most valued by long-term investors.
Diagnostics and Genomics (DGG) encompasses Agilent's pathology business (Dako-branded immunohistochemistry and in-situ hybridization products used in cancer diagnosis), the nucleic-acid solutions business (oligonucleotides, CRISPR components, and custom nucleic-acid synthesis for pharmaceutical and research customers), and the genomics portfolio (microarrays, target enrichment). DGG's revenue profile has been volatile — elevated during COVID by nucleic-acid demand for PCR-test manufacturing, then depressed as that demand normalized. The long-term thesis is that pathology consumables and therapeutic nucleic-acid manufacturing will provide durable recurring revenue, but the segment has yet to demonstrate the stability that CrossLab exhibits.
Unit economics at the instrument level are illustrative: a mid-range HPLC system sold at $100,000 generates roughly $15,000–$25,000 per year in consumables (columns, solvents, sample-preparation products) and $8,000–$15,000 per year in service revenue, for an annual aftermarket yield of $23,000–$40,000 on a $100,000 instrument — a 23%–40% annual revenue yield on the initial sale, sustained for 10–15 years. Over the instrument's lifetime, total aftermarket revenue can exceed the instrument purchase price by 3x to 5x.
Competitive Position and Moat
Agilent operates within a stable oligopoly that has been remarkably resistant to disruption for decades. The competitive landscape is defined by a small number of global players, each with deep technical capabilities, massive installed bases, and entrenched customer relationships.
Major analytical-instrument competitors and relative positioning
| Competitor | Revenue (FY2024 est.) | Key Strengths | Primary Overlap with Agilent |
|---|
| Thermo Fisher Scientific | ~$44B | Scale, breadth, pharma services | Mass spectrometry, chromatography, lab software |
| Waters Corporation | ~$2.9B | HPLC/UPLC dominance, pharma QC | Liquid chromatography, mass spectrometry |
| Danaher (Sciex, Beckman) | ~$24B (total) | DBS operating system, clinical diagnostics | Mass spectrometry, clinical workflows |
| Shimadzu Corporation | ~$3.8B (analytical segment) |
Agilent's moat sources:
-
Method and regulatory lock-in. As detailed in Part I, validated analytical methods create switching costs that are regulatory, not merely contractual. This is the deepest and most durable moat source. It applies most powerfully in pharmaceutical QC, environmental compliance, and food-safety testing.
-
Installed-base scale. Hundreds of thousands of instruments worldwide, each consuming Agilent-specific consumables and generating service demand. The installed base is the platform on which CrossLab's recurring revenue is built.
-
Application-science expertise. Agilent's library of published application notes — numbering in the thousands — functions as a soft standard that shapes method development across industries. No new entrant can replicate this library in less than a decade.
-
Global service infrastructure. Same-day or next-day service response in major markets, backed by a parts-and-consumables logistics network. This is particularly important in GMP-regulated environments where instrument downtime directly impacts production.
-
Breadth across analytical techniques. Agilent competes in chromatography (LC, GC), mass spectrometry, spectroscopy (UV-Vis, ICP-OES, ICP-MS, AAS), and cell analysis, enabling multi-instrument enterprise relationships that competitors with narrower portfolios cannot match.
Where the moat is weaker:
-
Academic and research markets. Switching costs are lower where methods are not formally validated. Price sensitivity is higher. Chinese competitors and Shimadzu compete effectively.
-
Diagnostics. DGG competes against deeply entrenched diagnostics companies (Roche Diagnostics, Danaher/Beckman, Abbott) with vastly larger installed bases and clinical-laboratory relationships.
-
China. Domestic instrument manufacturers are closing the technology gap, and government procurement policies increasingly favor local suppliers.
The Flywheel
Agilent's value creation follows a reinforcing cycle with five distinct links:
🔄
Agilent's Compounding Flywheel
How installed-base economics generate durable returns
1. Instrument PlacementAgilent sells a chromatograph or spectrometer into a laboratory. The sale is profitable on its own terms (mid-50s gross margin).
2. Method ValidationThe customer, often with Agilent application-science support, develops and validates an analytical method on the Agilent system. The method specifies Agilent-branded columns, reagents, and software.
3. Consumables & Service Lock-InThe validated method creates a multi-year (often multi-decade) demand for Agilent consumables and service at 60%+ gross margins. CrossLab enterprise agreements formalize the relationship.
4. Data & Software IntegrationOpenLab and laboratory-informatics platforms accumulate data, compliance records, and workflow configurations that deepen switching costs at the systems level.
5. ReinvestmentFree cash flow generated by the aftermarket funds R&D (next-generation instruments), application-science support (more methods), and M&A (more consumables and software businesses), expanding the installed base and increasing the aftermarket yield per instrument.
The flywheel's critical property is that it compounds — each turn is slightly larger than the last. As the installed base grows, aftermarket revenue grows. As aftermarket revenue grows, free cash flow grows. As free cash flow grows, investment capacity grows. As investment capacity grows, the next generation of instruments is more capable, the application-science library expands, and the CrossLab platform deepens, attracting more customers and more methods.
The flywheel's vulnerability is the instrument-placement step. If new instrument sales slow — as they did in FY2023–2024 — the growth rate of the installed base declines, and the flywheel's acceleration slows (though it does not reverse, because the existing installed base continues to consume). This is why Agilent's management obsesses over the leading indicator of instrument orders, and why the company's stock price reacts disproportionately to changes in instrument booking trends even though the aftermarket business is far more valuable on a present-value basis.
Growth Drivers and Strategic Outlook
Agilent's forward growth story rests on five specific vectors, each with measurable current traction:
1. PFAS and environmental-testing mandates. The EPA's 2024 PFAS drinking-water limits (4 ppt for PFOS and PFOA) are the most significant new regulatory requirement in environmental testing in decades. Agilent estimates the PFAS testing market alone could generate $500 million or more in cumulative instrument and consumables demand over the next five years, split among the major instrument companies. Agilent's triple-quadrupole LC-MS/MS systems and PFAS-specific column products are well-positioned.
2. Biologics and cell-and-gene therapy characterization. The shift from small-molecule to biologic drugs requires fundamentally more complex analytical workflows. Multi-attribute methods (MAMs), intact-mass analysis, and glycan profiling all require advanced LC-MS instrumentation and specialized consumables. Agilent's AdvanceBio column line and BioAccord mass-detection system target this workflow.
3. CrossLab expansion and enterprise penetration. CrossLab's organic growth rate of high-single-digits has room to accelerate as Agilent expands the scope of enterprise agreements to include software, digital services, and laboratory-asset management. The addressable market for laboratory-services outsourcing — currently estimated at $15–$20 billion globally — far exceeds Agilent's current penetration.
4. Battery and advanced-materials testing. The global buildout of EV battery manufacturing and semiconductor fabrication is creating new demand for trace-element analysis (ICP-MS, ICP-OES) and materials characterization. Agilent's spectroscopy portfolio is well-suited to these applications, which require detection at the parts-per-billion level.
5. Geographic expansion in India and Southeast Asia. As pharmaceutical manufacturing shifts from China to India (for geopolitical reasons) and Southeast Asia (for cost reasons), laboratory infrastructure follows. India is now Agilent's fastest-growing major market, and the company has been investing in local sales, service, and application-science capacity.
Management's long-term financial framework targets mid-to-high single-digit organic revenue growth, annual operating-margin expansion of 50–100 basis points, and double-digit earnings-per-share growth through the combination of organic growth, margin expansion, and capital return (buybacks and dividends).
Key Risks and Debates
1. China de-risking is structural, not cyclical. The most consequential risk to Agilent's long-term growth model is that China's shift toward domestic instrument procurement is not a temporary budget cycle but a permanent structural change. If China moves from ~20% of revenue to ~12–15% over the next five years — which is plausible under current policy trends — Agilent's organic growth algorithm requires above-trend performance in the rest of the world to compensate. Management has not publicly articulated a scenario plan for a structurally lower-China world.
2. Pharma concentration risk. Roughly one-third of Agilent's revenue depends on pharmaceutical and biotechnology R&D and manufacturing spending. The sector's capital-expenditure cycles are driven by patent cliffs (Humira, Keytruda), clinical-trial outcomes, biotech funding markets, and FDA policy — none of which Agilent controls. A sustained downturn in pharma capex (beyond the current COVID normalization) would compress both instrument sales and the growth rate of the installed base.
3. Thermo Fisher's scale advantages. Thermo Fisher Scientific, at nearly seven times Agilent's revenue, can invest in platform R&D, geographic coverage, and end-to-end laboratory solutions at a scale that Agilent cannot match. Thermo's acquisition of PPD (clinical research services) and its growing position in pharma outsourcing create a customer relationship that extends beyond the laboratory. As the analytical-instruments market converges with laboratory services, Agilent's relative scale disadvantage becomes more relevant.
4. DGG's uncertain trajectory. The Diagnostics and Genomics segment has underperformed expectations since the COVID-related demand surge ended. Pathology consumables face competition from larger diagnostics companies (Roche, Danaher). The nucleic-acid business is normalizing after the PCR-era boom. Genomics products (microarrays, target enrichment) face technology-transition risk as long-read sequencing and spatial-omics platforms mature. DGG needs to demonstrate organic growth stability or risk becoming a drag on Agilent's overall margin and valuation profile.
5. Software execution risk. Agilent's ambition to become the operating system of the analytical laboratory via OpenLab and digital-services platforms requires sustained investment in software engineering, cloud infrastructure, and user-experience design — capabilities that are culturally and operationally distant from the company's instrument-engineering core. If OpenLab fails to gain traction against Thermo Fisher's Chromeleon or Waters' Empower (or against next-generation cloud-native LIMS platforms from startups like Benchling or Sapio Sciences), the software strategy becomes a cost center rather than a competitive advantage.
Why Agilent Matters
Agilent Technologies is not a company that lends itself to breathless narratives. It does not disrupt. It does not pivot. It does not scale exponentially. What it does — with a precision that mirrors the instruments it manufactures — is compound.
The operating lessons are transferable to any business built on installed-base economics: the discipline of maximizing lifetime customer value over initial transaction value, the strategic patience to invest in aftermarket infrastructure that yields returns over decades rather than quarters, the organizational clarity that comes from ruthless simplification, and the recognition that in a regulated world, the deepest moats are built not by making the best product but by becoming inseparable from the customer's compliance infrastructure.
For investors, Agilent offers a rare combination of durability and capital efficiency — a business that generates $1.4 billion in free cash flow on $6.5 billion in revenue, protected by regulatory switching costs and an installed base that grows with each instrument shipped. The risks are real — China, pharma cyclicality, competitive scale — but they are the risks of a business that has already won its core markets and must now defend and extend them, which is a different and more manageable challenge than building from zero.
The columns keep shipping. The methods stay validated. The machine keeps compounding. That is the Agilent story — not a tale of disruption but of accretion, one molecular separation at a time.
